Development of passive immunity against SARS-CoV-2 for management of immunodeficient patients—a perspective - 22/07/20
Doi : 10.1016/j.jaci.2020.04.043
Lennart Hammarström, MD, PhD a, Hassan Abolhassani, MD, PhD a, Fausto Baldanti, MD, PhD b, Harold Marcotte, PhD a, Qiang Pan-Hammarström, MD, PhD c, ⁎ 
a Division of Clinical Immunology and Transfusion Medicine, Department of Laboratory Medicine, Karolinska Institutet at Karolinska University Hospital, Stockholm, Sweden
b Molecular Virology Unit, IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy
c Department of Biosciences and Nutrition, Karolinska Institutet, Huddinge, Sweden
∗Corresponding author: Qiang Pan-Hammarström, MD, PhD, Department of Biosciences and Nutrition, Neo, Karolinska Institutet, SE14183 Huddinge, Sweden.Department of Biosciences and NutritionNeo, Karolinska InstitutetHuddingeSE14183Sweden
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Key words : COVID-19, immunodeficiency, passive immunity, plasma therapy, IVIG, mAb
Le texte complet de cet article est disponible en PDF.
| This work was supported by the Swedish Research Council and the European Commission Horizon 2020 program (grant no. 101003650-ATAC). |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
© 2020
American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Vol 146 - N° 1
P. 58-60 - juillet 2020 Retour au numéro
Article précédent
- Does asthma affect morbidity or severity of COVID-19?
- Kenji Matsumoto, Hirohisa Saito
- Air pollution, racial disparities, and COVID-19 mortality
- Eric B. Brandt, Andrew F. Beck, Tesfaye B. Mersha
Bienvenue sur EM-consulte, la référence des professionnels de santé.